-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Extra-diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, mostly originated in the lymph nodes, but about 40% of cases originate outside the knot, the molecular pathological mechanism, clinical manifestations and prognosis of the out-of-the-knot DLBCL are different from the intine DLBCL.
recently, a retrospective study published in the journal Blood summarized the characteristics and prognosis of DLBCL in the Litoxi monoa resistance era.
The study included Phase I DLBCL patients treated with lysoxyrephine, cyclophosphamide, amycin, changchun new base, strong pine (R-CHOP) or R-CHOP-like programs in 2001-2015.
a total of 1,955 newly diagnosed DLBCL patients, 341 of whom were in Phase I, met the requirements and were included in the analysis.
out-of-knot performance was observed in 224 (66%) patients, and 117 (34%) patients had swollen lymph nodes.
most common colon lesions were bone (21 per cent), followed by the stomach (19 per cent), testicles (9 per cent), small intestine (8 per cent) and breast (8 per cent).
, 69 percent of patients with out-of-knot and 68 percent of end-of-life manifestations received RT treatment.
follow-up for 5.5 years.
10-year overall survival rate and disease-free survival rate were 77%, respectively.
in multivariable analysis, the OS and progression-free survival rates were worse in patients with non-lymph nodes (3.44 and 3.25, respectively).
in patients with out-of-knot effects, the consolidation of RT improved OS and PFS (HR 0.26 and 0.35, respectively), but this RT benefit was not observed in patients with PET negative after immunotherapy.
recurrence usually occurs later (37 months in the middle), with the most common relapses occurring in the lymph nodes (31%) and the central nervous system (27%).
, the prognosis of patients with DLBCL outside phase I was worse than that of patients with end-of-life.
results of PET tests after immunotherapy can help determine whether out-of-life patients need to undergo consolidation RT.
.
